Key facts
- It has raised $7.1M; the latest was Later Stage VC ($5.6M) in Dec 2025.
- Notable investors include Keiretsu Forum, AngelMD.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for OYE Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OYE Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OYE Therapeutics
Operator of a clinical-stage pharmaceutical development company intended to improve access to care by turning existing drugs into clinical solutions. The company seeks to establish a niche drug label claim using regulatory pathways to develop new uses for existing drugs, enabling the healthcare industry to improve the drug development process and patients' lives through the advancement of safe and effective drug therapies.
- Sector
- Healthcare
- HQ
- Crown Point, IN, United States
- Founded
- 2019
- Employees
- 10
- Website
- oyetherapeutics.com/
- Ownership
- Privately Held (backing)
OYE Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OYE Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OYE Therapeutics in its N-PORT filings yet. We sweep new filings monthly.